CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
0.21 ^USD	+5.47%		+0.72%	-83.46%

Apr. 23	Transcript : CNS Pharmaceuticals, Inc. - Special Call
Apr. 01	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019

December 20, 2019 at 04:04 pm EST

CNS Pharmaceuticals, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 699,094 compared to USD 169,905 a year ago. Net loss was USD 706,655 compared to USD 193,204 a year ago. Basic loss per share was USD 0.05 compared to USD 0.02 a year ago. For the nine months, operating loss was USD 1.309 million compared to USD 673,204 a year ago. Net loss was USD 1.349 million compared to USD 760,386 a year ago. Basic loss per share was USD 0.1 compared to USD 0.07 a year ago.

Latest news about CNS Pharmaceuticals, Inc.

Transcript : CNS Pharmaceuticals, Inc. - Special Call	Apr. 23
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees	Feb. 27	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	Jan. 30	MT
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell	Jan. 30	MT
CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors	Jan. 18	CI
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	Jan. 17	CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	Dec. 18	CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	Nov. 22	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : CNS Pharmaceuticals, Inc. - Pre Recorded Special Call	23-10-17
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland	23-10-11	CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme	23-09-07	CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy	23-08-14	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme	23-08-03	CI
Top Premarket Gainers	23-05-22	MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors	23-05-08	CI
Transcript : CNS Pharmaceuticals, Inc. - Special Call	23-05-03
Top Premarket Gainers	23-04-20	MT
Top Premarket Decliners	23-04-18	MT
Top Premarket Gainers	23-04-17	MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
CNS Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI

Chart CNS Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - LSX World Congress

More about the company

	1st Jan change	Capi.
CNS PHARMACEUTICALS, INC.	-83.46%	2.23M
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+47.24%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research